MONTREAL, April 11 /CNW TELBEC/ - Theratechnologies (TSX: TH) recently
received authorization from the Food and Drug Administration (FDA) in United
States to proceed to Phase III with its lead compound, ThGRF (TH9507), in HIV-
associated lipodystrophy. Phase III is the final stage of testing prior to
submitting a product for market approval. To mark this occasion, media
representatives are invited to meet members of Theratechnologies' management
team as they will give an update on ThGRF Phase III program. The press
conference will also be an opportunity to meet Dr. Julian Falutz, Assistant
Professor, McGill University Medical School, and leading authority on HIV-
associated lipodystrophy. Dr. Falutz is lead investigator for Canada in
Theratechnologies' lipodystrophy study. The Annual Meeting of Shareholders
will be held immediately after the press conference.
What: Press Conference and Annual General Meeting of Shareholders
Who: Mr. A. J. de GrandprDe, Chairman of the Board
Mr. Yves Rosconi, President and Chief Executive Officer
Mr. Luc Tanguay, Senior Executive Vice President
and Chief Financial Officer
Special guest: Dr. Julian Falutz, Director, HIV Metabolic Clinic,
-------------- MontrDeal General Hospital, Assistant Professor, McGill
University Medical School, and Lead Investigator for
Canada
Where: Centre Mont-Royal (corner of Sherbrooke Street)
2200 Mansfield Street
Salon l'International I-II, 2nd Floor
Montreal
When: Wednesday, April 13, 2005
Press conference at 9:00 am
Annual meeting at 10:00 am
About Theratechnologies
Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company
engaged in the discovery and development of therapeutic peptides in the field
of endocrinology and metabolism. The Company uses proprietary discovery
technologies to expand its product portfolio. The most advanced clinical
program (completed Phase II) targets HIV-associated lipodystrophy. Other
clinical programs are investigating wasting associated with chronic disease
and type 2 diabetes. Theratechnologies' website is located at
www.theratech.com .
PRESS CONFERENCE - Theratechnologies Inc. - Invitation to Media
Earlier from Theratechnologies
Later from Theratechnologies
- Theratechnologies reports on a positive meeting with Health Canada for its ThGRF Phase III program
- Theratechnologies: four scientific posters at the Endocrine Society Annual Meeting
- Theratechnologies closes the sale of its investment in Celmed BioSciences
- Theratechnologies launches Phase III clinical trial for TH9507 (ThGRF) treating HIV-associated lipodystrophy
- Theratechnologies: Financial results for the second quarter and recent operating highlights
Follow Theratechnologies into a list and get an email when it puts out news.
Follow Theratechnologies